產(chǎn)品名稱：Neopterin ELISA 產(chǎn) 地：Demeditec 產(chǎn)品貨號：DE65101 產(chǎn)品規(guī)格：96 Tests 產(chǎn)品說明： Special remarks: SUMMARY AND EXPLANATION Pteridines constitute a large and structurally varied group of natural compounds involved in the biosynthestic pathways of cofactors and vitamins (Fig. 1). Derivatives with the structure 2-amino-4-oxo are designated by the term "pterins" (Fig. 1) and can be divided into two groups: Conjugated Pterins Those derived from folic acid, containing a p-aminobenzoate plus glutamate Unconjugated Pterins Contain neither of these two groups, instead, a substitution occurs mainly at the 6-position of the ring nucleus Neopterin [D-erythro-neopterin], a 253.2 Da low-molecular-mass molecule, belongs to the group of pteridines. Neopterin as well as other pteridines are derived in vivo from guanosinetriphophate (GTP). The enzyme GTP-cyclohydrolase-I catalyses this reaction in monocytes and macrophages. Neopterin is excreted by activated macrophages, and can be determined in serum, plasma and other body fluids by immunoassay. Neopterin serves as a marker of cellular immune system activation, and it can be used as a prognostic predictor for certain types of diseases. Neopterin levels provide an especially valuable indicator of clinical activity in diseases characterised by acute changes in severity. The determination of neopterin levels in human body fluids offers a useful and innovative tool for monitoring diseases associated with the activation of cell-mediated immunity such as viral infections and graft rejection in transplantation. In addition, blood samples are usually not tested for all possible infections. Therefore, the measurement of neopterin in blood donor samples is a useful tool in order to reduce the risk of infections via blood transfusion. Neopterin concentrations may be significantly increased in other particular disease state compared to controls and serial measurements of neopterin concentrations in a particular patient may be useful in monitoring the course of a condition. Some potential diagnostic applications for the determination of neopterin are: -follow-up of traumatized ICU patients -prognostic indicator in HIV infections -early indication of graft-vs-host disease in bone-marrow transplant patients -early indication of episodes of graft rejection. -indicator of disease activity in autoimmune diseases -diagnosis of viral infections -differential diagnosis of acute viral and bacterial infections -prognostic indicator in malignant diseases -follow-up control of chronic infections -monitoring of immunostimulatory therapy PRINCIPLE OF THE TEST The Neopterin assay is a competitive enzyme immunoassay for the quantitative determination of neopterin in serum, plasma and urine using high affinity monoclonal antibody specific for neopterin. An unknown amount of antigen (neopterin) in the sample and a fixed amount of enzyme labelled antigen (neopterin bound horse radish peroxidase) compete for the antibody-binding sites (mouse monoclonal antibody against neopterin). Both antigen-monoclonal antibody complexes bind to the wells of the microtiter strips coated with a goat-anti-mouse antibody. Unbound antigen and conjugate (neopterin bound horse radish peroxidase) are removed by washing. The intensity of the color developed after the substrate incubation is directly proportional to the amount of bound conjugate and inversely proportional to the amount of neopterin in the standard or sample. Therefore, as the concentration of neopterin in the sample or standard increases, the intensity of the blue color will decrease. An acidic stop solution is added which changes the chromogen color from blue to yellow. The microwells are measured optically by a microplate reader with an absorbance filter of 450nm (OD450). The optical densities of the samples are compared to the OD’s of the kit standards and an interpretative result is determined. The results are calculated by plotting a Standard curve (optical density versus concentrations of neopterin standard), from which the neopterin concentrations in the patient samples can be read off directly. 上海玉博生物技術(shù)有限公司在為生命科學領(lǐng)域提供豐富的產(chǎn)品與信息資源方面處于國內(nèi)**地位，公司提供的產(chǎn)品涵蓋了二十多個國家近五十萬種產(chǎn)品，而且產(chǎn)品的數(shù)量與信息在不斷的增長和更新，公司提供的產(chǎn)品能夠使生命科學工作者加快對生物化學，分子生物學，細胞生物學以及蛋白質(zhì)組學研究的認知，以及分子診斷和臨床醫(yī)學領(lǐng)域的應用。
滬公網(wǎng)安備 31011002002623號
